Semaglutide works by mimicking a natural gut hormone called GLP-1 that your body releases after eating. This hormone normally helps regulate blood sugar, appetite, and digestion, but it breaks down within minutes. Semaglutide is engineered to last much longer, with a half-life of about 160 hours, which is why it only needs to be taken once a week. The result is a sustained signal that tells your brain you’re full, slows digestion, and helps your pancreas manage blood sugar more effectively.
How It Mimics a Natural Hormone
Every time you eat, cells in your intestines release GLP-1 (glucagon-like peptide-1). This hormone does several things at once: it signals your pancreas to produce insulin, tells your liver to stop dumping extra sugar into your blood, and communicates with your brain that food has arrived. The problem is that an enzyme called DPP-4 chews up natural GLP-1 within minutes, so its effects are fleeting.
Semaglutide is a modified version of this hormone, redesigned so DPP-4 can’t break it down as quickly. It binds to the same GLP-1 receptors throughout your body, but instead of lasting a few minutes, it circulates for days. That persistent activity is what makes semaglutide so much more powerful than the hormone your body produces on its own.
What Happens in Your Brain
The appetite-suppressing effects of semaglutide are largely driven by its actions in the brain, and the pathway is more complex than simply “flipping a hunger switch.” Research published in JCI Insight showed that semaglutide doesn’t actually cross the blood-brain barrier the way many drugs do. Instead, it reaches the brain through specific entry points called circumventricular organs, small regions where the barrier is naturally more permeable, along with several sites near the brain’s ventricles.
Once it reaches these areas, semaglutide activates neurons in at least 10 distinct brain regions. In the hypothalamus, it directly turns on neurons that produce satiety signals (called POMC/CART neurons) while simultaneously shutting down neurons that drive hunger (NPY/AgRP neurons). This is essentially a two-pronged approach: boosting the “I’m full” signal and silencing the “I’m hungry” signal at the same time.
The effects ripple outward from there. Semaglutide triggers activity in the brainstem’s area postrema and a relay station called the parabrachial nucleus, both of which are involved in processing appetite signals and the feeling of nausea. This cascading activation across multiple independent brain areas, rather than a single target, likely explains why semaglutide is so effective at reducing food intake. It’s not acting on one circuit. It’s influencing several at once.
Effects on Digestion
Semaglutide slows the rate at which your stomach empties food into your small intestine. This means meals sit in your stomach longer, which contributes to the feeling of fullness that lasts well beyond the meal itself. In a study of patients undergoing upper endoscopy, 24% of those taking semaglutide still had residual food in their stomachs before the procedure, compared to just 5% of patients not on the drug.
This delayed gastric emptying also helps smooth out blood sugar spikes after eating, since nutrients enter the bloodstream more gradually. For people with type 2 diabetes, that translates to better post-meal glucose control without the sharp highs and lows.
Blood Sugar Regulation
In the pancreas, semaglutide works on two hormones simultaneously. It stimulates insulin secretion when blood sugar is elevated and suppresses glucagon, a hormone that raises blood sugar by telling the liver to release stored glucose. Both of these effects are glucose-dependent, meaning they scale up when blood sugar is high and dial back when it’s normal. This built-in safety mechanism is why semaglutide on its own carries a low risk of causing dangerously low blood sugar.
The combination of increased insulin, reduced glucagon, and slower digestion is what makes semaglutide effective for managing type 2 diabetes. It addresses blood sugar from multiple angles rather than relying on a single mechanism.
Injectable vs. Oral Forms
Semaglutide comes in two delivery methods: a once-weekly injection (sold as Ozempic for diabetes and Wegovy for weight management) and a daily oral tablet (Rybelsus). The injectable form is straightforward, delivered just under the skin where it absorbs into the bloodstream.
The oral version posed a much bigger engineering challenge. Proteins like semaglutide are normally destroyed by stomach acid and digestive enzymes before they can be absorbed. To solve this, the tablet is co-formulated with an absorption enhancer called SNAC, a small fatty acid compound that does two things. First, it temporarily increases the permeability of the stomach lining so semaglutide molecules can pass through. Second, it neutralizes stomach acid in the tablet’s immediate vicinity, protecting the drug from being broken down. This is why the oral form must be taken on an empty stomach with only a small sip of water, and you need to wait at least 30 minutes before eating or drinking anything else. Food in the stomach interferes with this absorption process.
How Dosing Ramps Up
Semaglutide is started at a low dose and gradually increased over several weeks. For the injectable version used in diabetes (Ozempic), the schedule begins at 0.25 mg once weekly for four weeks. This starting dose isn’t meant to be therapeutic. It’s designed to let your body adjust and reduce the severity of side effects. After four weeks, the dose increases to 0.5 mg, which is the first maintenance level. Depending on how well blood sugar responds, it can be increased further to 1 mg and eventually to a maximum of 2 mg per week, with at least four weeks between each step up.
The weight management version (Wegovy) follows a similar escalation pattern but reaches a higher maintenance dose of 2.4 mg weekly. Each dose increase can bring a temporary return of side effects, which is why the slow titration matters.
Common Side Effects
Gastrointestinal issues are by far the most frequent side effects, which makes sense given how directly semaglutide affects the digestive system and the brainstem regions involved in nausea. In a large cross-sectional analysis from the National Institutes of Health’s All of Us cohort, abdominal pain was the most commonly reported issue at 57.6% of patients. Diarrhea affected 32.7%, constipation 30.4%, and nausea with vomiting 23.4%.
These numbers are higher than what’s typically reported in controlled clinical trials, likely because they reflect real-world use across a broader population. For most people, nausea and stomach discomfort are worst during the dose-escalation phase and improve as the body adjusts. A smaller percentage of patients (about 5%) develop gastroparesis, a more persistent slowing of stomach emptying that can require medical attention.
Cardiovascular Effects
Beyond blood sugar and weight, semaglutide has demonstrated cardiovascular benefits. The SELECT trial found that the 2.4 mg weekly dose reduced major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) by 20% compared to placebo in people with existing heart disease who were overweight or obese but did not have diabetes. This was a significant finding because it showed cardiovascular protection independent of blood sugar control, suggesting the drug’s benefits extend beyond its original purpose as a diabetes treatment.